Publications by authors named "Daniela Aldrighetti"

Claim this Profile
M
Management of Trastuzumab Deruxtecan-related nausea and vomiting in real-world practice.
Giulia Notini, Matteo Maria Naldini, Lorenzo Sica, Giulia Viale, Alessia Rognone, Daniela Aldrighetti

Front Oncol· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Personalized Risk-Benefit Ratio Adaptation of Breast Cancer Care at the Epicenter of COVID-19 Outbreak.
Giulia Viale, Luca Licata, Lorenzo Sica, Stefania Zambelli, Patrizia Zucchinelli, Daniela Aldrighetti

Oncologist· July 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A randomized, phase II, three-arm study of two schedules of ixabepilone or paclitaxel plus bevacizumab as first-line therapy for metastatic breast cancer.
Hope S Rugo, Mario Campone, Dino Amadori, Daniela Aldrighetti, Pierfranco Conte

Breast Cancer Res Treat· June 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An exploratory study of sunitinib in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive metastatic breast cancer.
Fatima Cardoso, Jean-Luc Canon, Dino Amadori, Daniela Aldrighetti, Jean-Pascal Machiels

Breast· December 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antiangiogenic strategies in breast cancer management.
Monica Giovannini, Daniela Aldrighetti, Patrizia Zucchinelli, Carmen Belli, Eugenio Villa

Crit Rev Oncol Hematol· October 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Switching to an aromatase inhibitor provides mortality benefit in early breast carcinoma: pooled analysis of 2 consecutive trials.
Francesco Boccardo, Alessandra Rubagotti, Daniela Aldrighetti, Franco Buzzi, Giorgio Cruciani

Cancer· March 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Concomitant versus sequential administration of epirubicin and paclitaxel as first-line therapy in metastatic breast carcinoma: results for the Gruppo Oncologico Nord Ovest randomized trial.
Pier Franco Conte, Valentina Guarneri, Paolo Bruzzi, Tiziana Prochilo, Barbara Salvadori, Daniela Aldrighetti

Cancer· August 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis